Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 393

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 393
---
 in the NOR test, using a 3 -daysinterval between the acquisition session (called sample trial) and the retention session (called choice trial). NLS -12dose -dependentlyimproved the recognition of the familiar object, i.e., improved memory. This effect was significant at 8 mg/kg and was not significantly different to that of donepezil. The recognition of the familiar object was not modified by NLS -12(1 mg/kg) and was improved in a non -significantmanner by NLS -12(4 mg/kg). The results of this pre -clinicalstudy suggest that NLS -12induced a long -termmemory improvement which was significant and of the same extent to that induced by donepezil. Aexon CNS Platform Aexon conducts research on new compounds to address unmet needs in neurodegenerative disorders, defined by the breakdown of neurons over time. Alzheimer’s, Parkinson’s, Huntington’s, Narcolepsy and Amyotrophic Lateral Sclerosis are just a few examples of brain disorders that have no cure. Eric Konofal, MD, PhD, who works under a part -timeconsulting agreement for NLS as its Chief Scientific Officer, is the president and founder of Aexon, and owns 59% of Aexon. Alexander Zwyer, NLS’s Chief Executive Officer, owns 35% of Aexon. Mr. Zwyer holds no board or executive position at Aexon. On March 20, 2024, NLS announced that it entered into an exclusive worldwide license agreement with Aexon, a privately held Delaware corporation, under which NLS acquired full global development and commercialization rights to Aexon’s Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin -1and orexin -2receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro -degenerativedisorders such as Parkinson’s and Alzheimer’s disease. This license agreement represents a potentially leading next -generation, first -in-class, oral, dual orexin receptor agonist platform that is expected to address high unmet medical needs and has shown promising results in pre -clinicalin vitro assays. NLSP has plans to initiate proof -of-conceptpreclinical development following the Merger, subject to sufficient funding. The possibility to acquire this novel and unique platform